NCT04631705View on ClinicalTrials.gov

SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

September 23, 2021

Study Completion Date

September 23, 2021

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

DZIF-10c

Inhaled administration of the human monoclonal antibody DZIF-10c

BIOLOGICAL

DZIF-10c

Intravenous administration of the human monoclonal antibody DZIF-10c

DRUG

Placebo

Inhalation of DZIF-10c diluent as placebo

DRUG

Placebo

Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo

Trial Locations (6)

20246

University Medical Center Hamburg-Eppendorf, Hamburg

35392

University Hospital Gießen and Marburg, Giessen

40225

University Hospital Düsseldorf, Düsseldorf

50937

University Hospital Cologne, Cologne

60590

University Hospital Frankfurt, Frankfurt am Main

81377

LMU Munich University Hospital, Munich

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

ZKS Köln

OTHER

collaborator

Boehringer Ingelheim

INDUSTRY

lead

University of Cologne

OTHER